Evogene Ltd. logo

Evogene Ltd.

EVGN

NASDAQHealthcareBiotechnology

Previous close

$0.5625

+$0.002 · +0.36%

Aug 21, 4:00 PM ET

EVGN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

29

Expensive

Momentum

20

Strong Down

Sentiment

60

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Ofer Haviv
Listed since
Oct 15, 2010
Employees
52

Market position

Day range

Current $0.5625

52-week range

Current $0.5625

Open
$0.5437
Previous close
$0.5605
Volume
1.04M
0.78× average
Average volume
1.33M
Average daily volume
Market cap
4.85M USD
Beta
0.78
Market reference 1
50-day average
$0.5336
+5.42% above average
200-day average
$0.8247
-31.79% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-2.1M USD
P/E (TTM)
-0.63×
P/B (TTM)
-2.16×
P/S (TTM)
3.82×
EV / EBITDA
0.17×
Earnings yield
-97.96%
Free cash flow yield
-157.44%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-14.16%
Operating margin
-1020.35%
Net margin
-696.26%
Return on equity
10347.56%
Return on assets
-42.33%
Return on invested capital
-81.04%

Financial health

Debt / equity
-0.64×
Current ratio
4.54×
Altman Z-score
-32.1
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends396%-958%-2313%-3667%Gross margin, FY2021: 17.53%Gross margin, FY2022: 45.73%Gross margin, FY2023: 50.03%Gross margin, FY2024: 57.32%Gross margin, FY2025: -6.25%Operating margin, FY2021: -3328.28%Operating margin, FY2022: -1608.42%Operating margin, FY2023: -745.51%Operating margin, FY2024: -337.17%Operating margin, FY2025: -364.24%Net margin, FY2021: -2988.49%Net margin, FY2022: -1590.33%Net margin, FY2023: -800.77%Net margin, FY2024: -295.59%Net margin, FY2025: -220.22%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 17.53%. Gross margin FY2022 45.73%. Gross margin FY2023 50.03%. Gross margin FY2024 57.32%. Gross margin FY2025 -6.25%. Operating margin FY2021 -3328.28%. Operating margin FY2022 -1608.42%. Operating margin FY2023 -745.51%. Operating margin FY2024 -337.17%. Operating margin FY2025 -364.24%. Net margin FY2021 -2988.49%. Net margin FY2022 -1590.33%. Net margin FY2023 -800.77%. Net margin FY2024 -295.59%. Net margin FY2025 -220.22%.

Income trends

Revenue

3.85M USD-30.91%

Operating income

−14.03M USD+25.37%

Net income

−8.49M USD+48.53%
Income trends across reported periods9.23M USD−5.38M USD−19.99M USD−34.61M USDRevenue, FY2021: 930K USDRevenue, FY2022: 1.68M USDRevenue, FY2023: 2.98M USDRevenue, FY2024: 5.58M USDRevenue, FY2025: 3.85M USDOperating income, FY2021: −30.95M USDOperating income, FY2022: −26.94M USDOperating income, FY2023: −22.23M USDOperating income, FY2024: −18.8M USDOperating income, FY2025: −14.03M USDNet income, FY2021: −27.79M USDNet income, FY2022: −26.64M USDNet income, FY2023: −23.88M USDNet income, FY2024: −16.49M USDNet income, FY2025: −8.49M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 930K USD. Revenue FY2022 1.68M USD. Revenue FY2023 2.98M USD. Revenue FY2024 5.58M USD. Revenue FY2025 3.85M USD. Operating income FY2021 −30.95M USD. Operating income FY2022 −26.94M USD. Operating income FY2023 −22.23M USD. Operating income FY2024 −18.8M USD. Operating income FY2025 −14.03M USD. Net income FY2021 −27.79M USD. Net income FY2022 −26.64M USD. Net income FY2023 −23.88M USD. Net income FY2024 −16.49M USD. Net income FY2025 −8.49M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.85M USD5.58M USD2.98M USD1.68M USD930K USD
Cost of goods sold4.09M USD2.38M USD1.49M USD909K USD767K USD
Gross profit−241K USD3.2M USD1.49M USD766K USD163K USD
Research and development7.99M USD12.51M USD16.2M USD20.79M USD21.13M USD
Selling, general, and administrative5.76M USD8.98M USD7.53M USD10.42M USD9.99M USD
Operating expenses13.79M USD22M USD23.72M USD27.71M USD31.12M USD
Interest income2.47M USD957K USD1.25M USD182K USD291K USD
Interest expense1.89M USD124K USD171K USD241K USD403K USD
Depreciation and amortization1.14M USD1.38M USD1.3M USD2.58M USD2.23M USD
Operating income−14.03M USD−18.8M USD−22.23M USD−26.94M USD−30.95M USD
Net income−8.49M USD−16.49M USD−23.88M USD−26.64M USD−27.79M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-151.81%
11 comparable reports
Latest EPS result
-0.13
Estimate -0.27 · Beat by 51.85%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.12-0.18-0.48-0.78Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 0.06, estimate -0.72, surprise +108.33%, Beat. Q2 2025, reported May 21, 2025: actual -0.38, estimate -0.625, surprise +39.20%, Beat. Q3 2025, reported Aug 19, 2025: actual -0.62, estimate -0.63, surprise +1.59%, Beat. Q4 2025, reported Nov 20, 2025: actual -0.31, estimate -0.26, surprise -19.23%, Miss. Q1 2026, reported Mar 5, 2026: actual -0.61, estimate -0.26, surprise -134.62%, Miss. Q2 2026, reported May 20, 2026: actual -0.6, estimate -0.27, surprise -122.22%, Miss. Q3 2026, reported Aug 18, 2026: actual -0.13, estimate -0.27, surprise +51.85%, Beat. Q4 2026, reported Nov 18, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.38M3.66M1.95M233.75KQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 1.61M USD, estimate 5M USD, surprise -67.78%, Miss. Q2 2025, reported May 21, 2025: actual 2.44M USD, estimate 1.94M USD, surprise +25.82%, Beat. Q3 2025, reported Aug 19, 2025: actual 884K USD, estimate 930K USD, surprise -4.95%, Miss. Q4 2025, reported Nov 20, 2025: actual 312K USD, estimate 275K USD, surprise +13.45%, Beat. Q1 2026, reported Mar 5, 2026: actual 314K USD, estimate 275K USD, surprise +14.18%, Beat. Q2 2026, reported May 20, 2026: actual 334K USD, estimate 350K USD, surprise -4.57%, Miss. Q3 2026, reported Aug 18, 2026: actual 347K USD, estimate 325K USD, surprise +6.77%, Beat. Q4 2026, reported Nov 18, 2026: actual —, estimate 400K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.15

282.22% upside
Past 12 months12-month forecast

Price history unavailable

High $2.15Average $2.15Low $2.15

EVGN news

EVGN peers

Continue in GoAI

Research EVGN

research.disclaimer